Alnylam reports additional positive interim phase 1 results for aln-app, in development for alzheimer's disease and cerebral amyloid angiopathy

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny) today announced additional positive interim results for the ongoing single ascending dose portion of the phase 1 study of aln-app, an investigational rnai therapeutic targeting amyloid precursor protein (app) in development for the treatment of alzheimer's disease and cerebral amyloid angiopathy (caa). the data were presented today in a late-breaker session at the 16th clinical trials on alzheimer's disease (ctad) c.
ALNY Ratings Summary
ALNY Quant Ranking